Literature DB >> 35752612

Pseudomonas aeruginosa: pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics.

Shugang Qin1, Wen Xiao1, Chuanmin Zhou2,3, Qinqin Pu3, Xin Deng4, Lefu Lan5, Haihua Liang6, Xiangrong Song7, Min Wu8,9.   

Abstract

Pseudomonas aeruginosa (P. aeruginosa) is a Gram-negative opportunistic pathogen that infects patients with cystic fibrosis, burn wounds, immunodeficiency, chronic obstructive pulmonary disorder (COPD), cancer, and severe infection requiring ventilation, such as COVID-19. P. aeruginosa is also a widely-used model bacterium for all biological areas. In addition to continued, intense efforts in understanding bacterial pathogenesis of P. aeruginosa including virulence factors (LPS, quorum sensing, two-component systems, 6 type secretion systems, outer membrane vesicles (OMVs), CRISPR-Cas and their regulation), rapid progress has been made in further studying host-pathogen interaction, particularly host immune networks involving autophagy, inflammasome, non-coding RNAs, cGAS, etc. Furthermore, numerous technologic advances, such as bioinformatics, metabolomics, scRNA-seq, nanoparticles, drug screening, and phage therapy, have been used to improve our understanding of P. aeruginosa pathogenesis and host defense. Nevertheless, much remains to be uncovered about interactions between P. aeruginosa and host immune responses, including mechanisms of drug resistance by known or unannotated bacterial virulence factors as well as mammalian cell signaling pathways. The widespread use of antibiotics and the slow development of effective antimicrobials present daunting challenges and necessitate new theoretical and practical platforms to screen and develop mechanism-tested novel drugs to treat intractable infections, especially those caused by multi-drug resistance strains. Benefited from has advancing in research tools and technology, dissecting this pathogen's feature has entered into molecular and mechanistic details as well as dynamic and holistic views. Herein, we comprehensively review the progress and discuss the current status of P. aeruginosa biophysical traits, behaviors, virulence factors, invasive regulators, and host defense patterns against its infection, which point out new directions for future investigation and add to the design of novel and/or alternative therapeutics to combat this clinically significant pathogen.
© 2022. The Author(s).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35752612      PMCID: PMC9233671          DOI: 10.1038/s41392-022-01056-1

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  475 in total

1.  Overexpression and initial characterization of the chromosomal aminoglycoside 3'-O-phosphotransferase APH(3')-IIb from Pseudomonas aeruginosa.

Authors:  Mariana Hainrichson; Orit Yaniv; Marina Cherniavsky; Igor Nudelman; Dalia Shallom-Shezifi; Sima Yaron; Timor Baasov
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

2.  Engineered bacterial outer membrane vesicles with enhanced functionality.

Authors:  Jae-Young Kim; Anne M Doody; David J Chen; Gina H Cremona; Michael L Shuler; David Putnam; Matthew P DeLisa
Journal:  J Mol Biol       Date:  2008-04-09       Impact factor: 5.469

3.  Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA.

Authors:  Gregory M Barton; Jonathan C Kagan; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2005-12-11       Impact factor: 25.606

4.  Lipase LipC affects motility, biofilm formation and rhamnolipid production in Pseudomonas aeruginosa.

Authors:  Frank Rosenau; Silke Isenhardt; Aneta Gdynia; Denis Tielker; Ernst Schmidt; Petra Tielen; Max Schobert; Dieter Jahn; Susanne Wilhelm; Karl-Erich Jaeger
Journal:  FEMS Microbiol Lett       Date:  2010-05-17       Impact factor: 2.742

5.  Identification of a potent inhibitor of type II secretion system from Pseudomonas aeruginosa.

Authors:  Wieslaw Swietnicki; Anna Czarny; Lukasz Antkowiak; Ewa Zaczynska; Monika Kolodziejczak; Jordan Sycz; Lukasz Stachowicz; Michalina Alicka; Krzysztof Marycz
Journal:  Biochem Biophys Res Commun       Date:  2019-04-12       Impact factor: 3.575

6.  Identification of critical residues in the propeptide of LasA protease of Pseudomonas aeruginosa involved in the formation of a stable mature protease.

Authors:  Kerian K Grande; Jean K Gustin; Efrat Kessler; Dennis E Ohman
Journal:  J Bacteriol       Date:  2007-03-09       Impact factor: 3.490

7.  RsaL provides quorum sensing homeostasis and functions as a global regulator of gene expression in Pseudomonas aeruginosa.

Authors:  Giordano Rampioni; Martin Schuster; Everett Peter Greenberg; Iris Bertani; Marco Grasso; Vittorio Venturi; Elisabetta Zennaro; Livia Leoni
Journal:  Mol Microbiol       Date:  2007-12       Impact factor: 3.501

8.  Extended-spectrum β-lactamases in Gram Negative Bacteria.

Authors:  Deepti Rawat; Deepthi Nair
Journal:  J Glob Infect Dis       Date:  2010-09

9.  Type VI secretion system of Pseudomonas aeruginosa is associated with biofilm formation but not environmental adaptation.

Authors:  Lihua Chen; Yaru Zou; Asmaa Abbas Kronfl; Yong Wu
Journal:  Microbiologyopen       Date:  2020-01-21       Impact factor: 3.139

Review 10.  Electrochemical Detection of Pyocyanin as a Biomarker for Pseudomonas aeruginosa: A Focused Review.

Authors:  Fatima AlZahra'a Alatraktchi; Winnie E Svendsen; Søren Molin
Journal:  Sensors (Basel)       Date:  2020-09-13       Impact factor: 3.576

View more
  2 in total

Review 1.  Conquering the host: Bordetella spp. and Pseudomonas aeruginosa molecular regulators in lung infection.

Authors:  Alina M Holban; Courtney M Gregoire; Monica C Gestal
Journal:  Front Microbiol       Date:  2022-09-26       Impact factor: 6.064

2.  Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler.

Authors:  Brieuc Van Nieuwenhuyse; Dimitri Van der Linden; Olga Chatzis; Cédric Lood; Jeroen Wagemans; Rob Lavigne; Kaat Schroven; Jan Paeshuyse; Catherine de Magnée; Etienne Sokal; Xavier Stéphenne; Isabelle Scheers; Hector Rodriguez-Villalobos; Sarah Djebara; Maya Merabishvili; Patrick Soentjens; Jean-Paul Pirnay
Journal:  Nat Commun       Date:  2022-09-29       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.